Probiotic E. coli Attenuates UTI Pain via TLR4 Interference
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for urinary tract infections (UTIs) often rely on antibiotics, which can lead to antimicrobial resistance, and the mechanisms underlying UTI-induced pain remain unclear, necessitating alternative approaches for pain management and infection treatment.
Innovation Solution
Administration of probiotic compositions, including asymptomatic E. coli strains like 83972 and 2-12, which act through TLR4-dependent pathways to reduce pain independently of inflammation, offering a novel strategy for treating UTI-related pain without contributing to antimicrobial resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat UTIs, then infection is effectively treated, but antimicrobial resistance develops
Solution Approach 1:
The patent introduces probiotic bacteria as intermediary agents that mediate between the pathogenic E. coli and the host immune system. These probiotics modulate the inflammatory response and interfere with TLR4-dependent pain pathways, providing treatment benefits without directly killing the pathogen, thus avoiding the selection pressure that drives antimicrobial resistance
Solution Approach 2:
The patent replaces the mechanical/chemical killing mechanism of traditional antibiotics with a biological modulation mechanism. Instead of directly eliminating the pathogen through antimicrobial action, the probiotics substitute a immune-modulating and pain-interfering mechanism that achieves treatment goals without the harmful side effect of resistance selection
2Reliability
If antibiotics are used to treat UTIs, then infection is cleared, but reliance on antibiotics increases
Solution Approach 1:
The patent positions probiotic bacteria as multi-functional agents that can treat both active UTIs and persistent pain symptoms, while also serving as a preventive measure. This universal approach provides treatment options for multiple conditions (active infection, pain management, prevention) without requiring different classes of drugs, thereby reducing overall antibiotic reliance
Solution Approach 2:
The probiotic composition appears to be self-regulating and does not require the same level of medical intervention or antibiotic prescription that traditional UTI treatments require. The formulation naturally modulates the immune response and interferes with pain pathways, providing a self-managing treatment approach that reduces dependency on antibiotic medications
3Object-affected harmful factors
If TLR4-dependent pathways are targeted for pain relief, then pain is effectively reduced, but inflammation may be affected
Solution Approach 1:
The patent applies local quality by specifically targeting the TLR4 pathway in the context of UTI-induced pain without necessarily suppressing systemic inflammation. The probiotic bacteria locally interfere with TLR4 signaling in the urinary tract and pelvic regions, providing pain relief while preserving the body's overall inflammatory defense mechanisms
Solution Approach 2:
The patent converts the harmful TLR4-mediated pain signaling into a beneficial target for intervention. By using probiotics to interfere with TLR4-dependent pathways, the harmful pain response is transformed into an opportunity for targeted pain management that spares other inflammatory processes, effectively turning a harmful pathway into a treatable target
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The probiotic compositions effectively attenuate UTI-induced pelvic pain by interfering with TLR4-dependent pain pathways, providing a non-inflammation-based treatment approach that minimizes the reliance on antibiotics and addresses the symptoms driving patient visits without promoting resistance.
Implementation Method 1
probiotic compositions act through TLR4-dependent pathways to reduce pain independently of inflammation
Data Source
AI summary
The present invention provides compositions and methods for treatment or prevention of pain resulting from infection, infection related pain, and non-infectious pain as well as treatment or prevention of infections or adverse health consequences associated with infections.